研究人员在1月24日出版的美国《癌症》（Cancer）期刊上发表文章说，常用乳腺癌治疗药物它莫西芬可能有助于降低肺癌致死风险。
先前研究显示，女性在绝经期采取荷尔蒙替代疗法刺激雌激素分泌，会增加患乳腺癌、肺癌或卵巢癌的风险。
它莫西芬是一种抗雌激素，能够抑制部分乳腺癌细胞生长和分裂。研究人员假设，这类抗雌激素在阻止雌激素分泌的同时，可能降低肺癌致死风险。
这个研究团队在瑞士日内瓦一家癌症统计机构选取6655名女性的数据，这些女性1980年至2003年间确诊患乳腺癌，其中3066人服用抗雌激素药物。
研究人员追踪截至2007年12月的全部乳腺癌患者病情进展，统计其中罹患肺癌和肺癌致死人数。
结果显示，与普通人群相比，这3066名服用抗雌激素药物的乳腺癌患者中，肺癌致死人数减少87%。
研究领队伊丽莎白·拉皮蒂说，统计结果支持研究假设，即体内荷尔蒙水平与肺癌存在关联，大部分乳腺癌患者罹患肺癌，与服用孕酮等雌激素有关。
拉皮蒂说，如果进一步研究能够证实这些统计结果，找到抗雌激素类药物有助于缓解肺癌的证据，将对今后临床研究产生重要影响。（生物谷Bioon.com）
生物谷推荐原文出处：
Cancer DOI: 10.1002/cncr.25638
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens
Christine Bouchardy MD1,*,§, Simone Benhamou DSc2,3, Robin Schaffar MSc1, Helena M. Verkooijen MD1,4, Gerald Fioretta MSc1, Hyma Schubert MSc1, Vincent Vinh-Hung MD5, Jean-Charles Soria MD6, Georges Vlastos MD7, Elisabetta Rapiti MD1
Keywords:lung cancer;breast cancer;mortality risk;anti-estrogens;epidemiology;population-based study
Abstract
BACKGROUND:
The Women's Health Initiative randomized clinical trial reported that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of anti-estrogens should be associated with decreased lung cancer mortality risk. The authors compared lung cancer incidence and mortality among breast cancer patients with and without anti-estrogen therapy.
METHODS:
Our study included all 6655 women diagnosed with breast cancer between 1980 and 2003 and registered at the Geneva Cancer Registry. Among these women, 46% (3066) received anti-estrogens. All women were followed for occurrence and death from lung cancer until December 2007. The authors compared incidence and mortality rates among patients with and without anti-estrogens with those expected in the general population by Standardized Incidence Ratios (SIRs) and Standardized Mortality Ratios (SMRs).
RESULTS:
After a total of 57,257 person-years, 40 women developed lung cancer. SIRs for lung cancer were not significantly decreased among breast cancer patients with and without anti-estrogens (0.63, 95% confidence intervals [CI], 0.33-1.10; and 1.12, 95% CI, 0.74-1.62, respectively) while SMR was decreased among women with anti-estrogens (0.13, 95% CI, 0.02-0.47, P<.001) but not for women without anti-estrogens (0.76, 95% CI, 0.43-1.23).
CONCLUSIONS:
Compared with expected outcomes in the general population, breast cancer patients receiving anti-estrogen treatment for breast cancer had lower lung cancer mortality. This study further supports the hypothesis that estrogen therapy modifies lung cancer prognosis. Cancer 2011. ? 2011 American Cancer Society.
